Recent events
Recent events tied to this brand in public sources.
Back to profile11 entries
2023
Mydecine announces board departure and appointment
Mydecine announced that Todd Heinzl resigned from its board and that Neil Stevenson-Moore was appointed as an independent director and audit committee member, effective April 3, 2023.
2021
Mydecine announces Michael Connolly's board resignation
Mydecine announced Michael Connolly's resignation from its Board of Directors and said Josephine Wu replaced him on the board.
2021
Mydecine appoints Josephine Wu to its board
Mydecine Innovations Group announced Josephine Wu's appointment to its Board of Directors.
2021
Mydecine appoints Gordon Neal to its board
Mydecine announced that it appointed Gordon Neal to its board of directors.
2021
Mydecine names Dean Ditto chief financial officer
Mydecine announced that Dean Ditto had joined the company as chief financial officer.
2021
Mydecine sponsors microdosing study at Macquarie University
Mydecine announced that it is sponsoring a study titled “The neurocognitive effects of low dose psychoactive substances” at Macquarie University in Australia.
2020
Mydecine and Microdose partner on webinar series
Mydecine Innovations Group announced a partnership with Microdose Psychedelic Insights to present a free, three-part live video discussion series titled “Mydecine Speaker Series.”
2020
Mindleap launches its mental health mobile app
Mindleap, a subsidiary of Mydecine Innovations Group, launched its mental health mobile application, which was available for download on iOS and Android on September 30, 2020.
2020
Mydecine announces licensed production and distribution capabilities for natural-source psilocybin
Mydecine announced that it was the first organization to exercise its cGMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin derived from whole-mushroom extraction.
2020
Mydecine establishes research agreement with Applied Pharmaceutical Innovation
Mydecine announced a research division agreement with Applied Pharmaceutical Innovation, providing access to drug-development expertise, facilities and licenses for research and development.
2020
NewLeaf Brands announces name and symbol change to Mydecine Innovations Group
NewLeaf Brands announced a name and symbol change to Mydecine Innovations Group; trading under the new name and symbol was scheduled to begin June 5, 2020.